Abstract
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Current Vascular Pharmacology
Title:Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?
Volume: 10 Issue: 4
Author(s): Elena Burillo, Paula Martin-Fuentes, Rocio Mateo-Gallego, Lucia Baila-Rueda, Ana Cenarro, Emilio Ros and Fernando Civeira
Affiliation:
Keywords: Omega-3 PUFAs, high-density lipoprotein, eicosapentaenoic acid and docosahexaenoic acid, atherosclerosis, apolipoproteins, proteome, CVD, coagulation, fibrinolysis
Abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) from marine origin have been strongly associated with cardiovascular protection, even at low doses (< 1g/d). Despite the research performed in this promising area, basic aspects, such as the ideal doses and the mechanisms by which ω-3 PUFAs act, are not precisely defined. The best known biological property of ω-3 PUFAs is their hypotriglyceridemic effect, but other cardioprotective actions, such as reduction of arrhythmia susceptibility, antithrombotic, antiinflammatory and antioxidant effects, improvement of endothelial function, and delayed atherosclerosis development have received an increased interest in recent years. Some of these actions are also ascribable to high-density lipoproteins (HDL). Abundant epidemiological evidence links increasing HDL-cholesterol concentrations to cardiovascular protection. Recently, the protein cargo (proteome) of HDL particles has been attributed a key role in their functionality. In this review, we summarize the main effects of ω-3 PUFAs on HDL-cholesterol, HDL subfractions, and its main proteins, apolipoproteins (apo) AI and AII. The shared cardioprotective actions of ω-3 PUFAs and HDL are reviewed as well.
Export Options
About this article
Cite this article as:
Burillo Elena, Martin-Fuentes Paula, Mateo-Gallego Rocio, Baila-Rueda Lucia, Cenarro Ana, Ros Emilio and Civeira Fernando, Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812845
DOI https://dx.doi.org/10.2174/157016112800812845 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review: Therapeutic Targeting of HMGB1 in Stroke
Current Drug Delivery Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Cardiovascular & Hematological Agents in Medicinal Chemistry Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews In Vitro Data of Current Therapies for SARS-CoV-2
Current Medicinal Chemistry “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Cellular Cholesterol Efflux Pathways: Impact on Intracellular Lipid Trafficking and Methodological Considerations
Current Pharmaceutical Biotechnology Non-Genomic Regulation of Cardiac Ion Channels by Sex Hormones
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Epigenetic Modulations in Kidney Podocytes: A Possible Target of Treatment for Proteinuria)
Current Hypertension Reviews Endothelial Dysfunction: The Link Between Homocysteine and Hydrogen Sulfide
Current Medicinal Chemistry The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Heat Stress Nephropathy: What Have We Learned?
Endocrine, Metabolic & Immune Disorders - Drug Targets Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Determination of the Sodium Concentration in Brazilian Light and Non- Light Powdered Instant Soups by Flame Photometry
Current Nutrition & Food Science Mechanisms of Endothelial Dysfunction and Cardiovascular System Adaptation
Current Vascular Pharmacology Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies Bioinformatics Tools for Mass Spectroscopy-Based Metabolomic Data Processing and Analysis
Current Bioinformatics Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography
Current Pharmaceutical Analysis Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Aging and Immune-Mediated Diseases (Guest Editors: Christian Dejaco, Christina Duftner and Michael Schirmer)]
Current Immunology Reviews (Discontinued)